Overview

Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)

Status:
Completed

Trial end date:
2008-03-01

Target enrollment:

Participant gender:

Summary

This study intends to study the efficacy and tolerability of once daily 3.0 g mesalazine granules vs. once daily 1.5 g mesalazine granules vs. three times daily 0.5 g mesalazine granules for maintenance of remission in patients with ulcerative colitis

Phase:

Phase 3

Details

Lead Sponsor:

Dr. Falk Pharma GmbH

Treatments:

Mesalamine